GlassScriptPhysician profile
Michael Stewart
NPI 1154604205
$6,678.89
in general payments reported to CMS, 2019-2025
16 companies · $3,429 in 2025
The $3,429 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $684 · 2023: $1,287 · 2024: $952 · 2025: $3,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,492 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,492.39 |
| Education | $175.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,194.76 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,132.33 | 2022-2025 | Caplyta |
| Alkermes, INC. | $913.10 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $666.49 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $664.67 | 2021-2025 | Ingrezza |
| Indivior INC. | $467.64 | 2023-2025 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $460.87 | 2024-2025 | Cobenfy |
| Abbvie INC. | $309.18 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $293.21 | 2023-2025 | Uzedy, Austedo Xr |
| Lundbeck LLC | $274.00 | 2023-2025 | Rexulti |
| Braeburn INC. | $125.00 | 2025 | Brixadi |
| Luye Pharma (USA) LTD. | $48.13 | 2025 | Erzofri Extended-Release |
| Axsome Therapeutics, INC. | $43.06 | 2023-2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $41.57 | 2022 | |
| Aimmune Therapeutics, INC. | $23.86 | 2025 | Vowst |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $21.02 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.